Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.65 |
| ▸ | MAOB | P27338 | 6/20 | 0.65 |
| ▸ | EGFR | P00533 | 9/20 | 0.54 |
| ▸ | GAK | O14976 | 1/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.48 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22967391 | 0.85 | MRGPRX4 (0.52) | MRGPRX4MAOBEGFRERBB2 | |
| SCHEMBL22967413 | 0.85 | EGFR (0.51) | MRGPRX4MAOBEGFRGAKERBB2 | |
| SCHEMBL18805044 | 0.83 | MRGPRX4 (0.64) | MRGPRX4MAOBEGFRGAKERBB2 | |
| SCHEMBL11910290 | 0.83 | MRGPRX4 (0.64) | MRGPRX4MAOBEGFRGAKERBB2 | |
| SCHEMBL11960847 | 0.82 | EGFR (0.56) | MRGPRX4MAOBEGFRGAKERBB2 | |
| SCHEMBL22874527 | 0.81 | EGFR (0.55) | MRGPRX4EGFRGAKERBB2PTPN7 | |
| SCHEMBL25648997 | 0.81 | EGFR (0.55) | MRGPRX4MAOBEGFRGAKERBB2 | |
| SCHEMBL17050818 | 0.81 | MRGPRX4 (0.60) | MRGPRX4MAOBENPP2 | |
| SCHEMBL21340832 | 0.81 | MAOB (0.79) | MRGPRX4MAOB | |
| SCHEMBL24388658 | 0.80 | CYP1A2 (0.61) | MAOBEGFRGAKERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548900-B2 | Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2023-01-10 | — | — | US | disclosed |
| EP-3760633-B1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2021-12-15 | — | — | EP | disclosed |
| US-20210040114-A1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF | ACCSALUS BIOSCIENCES LIMITED (VG) | 2021-02-11 | — | — | US | disclosed |
| EP-3760633-A1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-01-06 | — | — | EP | disclosed |
| WO-2019170088-A1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | 北京赛特明强医药科技有限公司 | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548900-B2 | Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof | WNK1, WNK2, WNK3 | MRGPRX4 3089/4885MAOB 975/4885EGFR 3163/4885 |
| US-20210040114-A1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF | WNK1, WNK2, WNK3 | MRGPRX4 3089/4885MAOB 975/4885EGFR 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.